文献速递皮肤肿瘤

人工智能智能手机应用检测皮肤癌的前瞻性诊断准确性研究

Artificial intelligence-based smartphone application for skin cancer detection: a prospective diagnostic accuracy study.
PubMed 文献 · Br J Dermatol · 2026-01-01

该前瞻性研究纳入1458例参与者的1904个关切皮损,评估一款广泛使用的皮肤癌检测应用(SkinVision)的AI卷积神经网络(CNN)诊断准确性。结果显示,图像采集失败率为16.6%,成功采集时CNN检测皮肤癌的敏感性为82.5%、特异性为76.8%;联合远程皮肤科审查后特异性升至86.8%,但敏感性降至75.3%。

要点

  • 在理想条件下,该应用图像采集失败率达16.6%(317/1904)。
  • CNN检测皮肤癌敏感性82.5%、特异性76.8%;联合远程审查后特异性86.8%、敏感性75.3%。
  • 用户自行拍摄时图像采集成功率仅28.9%,且不同智能手机型号间诊断性能存在差异。

核心结论

  • 该独立前瞻性研究在真实用户代表性队列中评估了广泛使用的皮肤癌检测应用的诊断性能。
  • 研究结果强调在真实世界环境中对基于AI的医疗工具进行独立临床验证的重要性。

研究设计与样本

  • 前瞻性诊断准确性研究,于2021年2月1日至2023年6月30日连续纳入因关切皮损就诊的参与者。
  • 共纳入1458例参与者的1904个关切皮损,其中185个(9.7%)为皮肤癌,包括32例黑色素瘤。
  • 每个皮损经皮肤科评估后使用应用拍摄,应用CNN生成二分类风险输出和建议,部分病例进行远程皮肤科审查。
  • 将CNN联合远程皮肤科审查的诊断准确性对照最终临床或组织病理学诊断,并在不同拍摄条件(角度、光照、拍摄者)和不同智能手机型号下测试性能。
  • 试验注册于ClinicalTrials.gov(NCT05246163)。

主要发现

  • 在成功采集的图像中,CNN检测皮肤癌的敏感性为82.5%,特异性为76.8%。
  • 应用内远程皮肤科审查覆盖65.7%(1042/1587)的图像,联合CNN后特异性提高至86.8%(P < 0.001),敏感性为75.3%。
  • 黑素细胞性病变的总体敏感性低于非黑素细胞性病变(71.0% vs. 76.3%;P < 0.001),而特异性更高(90.0% vs. 84.9%;P < 0.001)。
  • 图像采集在16.6%的皮损中失败(317/1904),尽管条件理想;用户自行拍摄的子研究显示图像采集成功率仅28.9%,且不同智能手机型号间诊断性能存在差异。

临床怎么用

  • 该应用在真实世界中的图像采集失败率较高,用户自行拍摄时成功率更低,临床使用时需关注图像质量对诊断的影响。
  • 联合远程皮肤科审查可提高特异性但降低敏感性,需权衡漏诊风险与假阳性。
  • 不同智能手机型号可能影响诊断性能,实际应用中应考虑设备差异。

局限性

  • 图像采集在理想条件下仍有16.6%失败,用户自行拍摄成功率仅28.9%,可能影响真实世界适用性。
  • 远程皮肤科审查仅覆盖65.7%的图像,联合分析受限。
  • 不同智能手机型号间诊断性能存在差异,可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Smartphone applications ('apps') that use artificial intelligence (AI) for skin cancer diagnosis may help with early detection. However, prospective studies assessing real-world performance are scarce. OBJECTIVES: To evaluate in an independent prospective study the diagnostic accuracy of a widely used skin cancer detection app and the effect of photographic conditions in a user-representative cohort of patients consulting for lesions of concern. METHODS: Between 1 February 2021 and 30 June 2023, participants presenting at an early-access consultation with a lesion of concern were consecutively enrolled. Following dermatological assessment, each lesion was photographed using the app. The app's convolutional neural network (CNN) generates a binary risk output and advice. A teledermatology review was performed in a subset of cases. The diagnostic accuracy of the CNN combined with teledermatology review was compared with final clinical or histopathological diagnosis. Performance was tested under different photographic conditions (angle, lighting, user) and with different smartphone models. The trial was registered with ClinicalTrials.gov (NCT05246163). RESULTS: A total of 1458 participants with 1904 lesions of concern were included. Of these, 185 (9.7%) were skin cancers, with 32 melanomas. Image capture was unsuccessful in 16.6% of lesions (n = 317/1904), despite optimal conditions. For successfully captured lesions, the CNN achieved a sensitivity of 82.5% and specificity of 76.8% for skin cancer detection. In-app teledermatology review was available for 65.7% (n = 1042/1587) of images. Combined CNN and teledermatology review resulted in increased specificity (86.8%; P < 0.001), with a sensitivity of 75.3%. Overall sensitivity in melanocytic lesions was lower than in nonmelanocytic lesions (71.0% vs. 76.3%; P < 0.001), whereas specificity was higher (90.0% vs. 84.9%; P < 0.001). A substudy demonstrated low image-capture success in user hands (28.9%) and variation in diagnostic performance between smartphone models. CONCLUSIONS: This independent, prospective study evaluated diagnostic performance of a widely used skin cancer detection app in a user-representative cohort. The findings highlight the importance of independent clinical validation of AI-based healthcare tools in real-world settings. Skin cancer is one of the most common cancers that affects people worldwide. Finding cancer early is important, especially for melanoma, a serious form of skin cancer. There is potential for smartphone apps to use AI to help people identify skin spots that may need medical attention. In this study, we evaluated a widely used app called SkinVision. People presenting with a worrisome spot at a dermatology appointment were invited to take part in this study. Altogether, 1458 people were included. The skin area of concern was assessed with the app. Using AI, the app produced a risk score. It also gave a final score. The final score was the AI risk score that may be combined with dermatology advice delivered remotely (‘teledermatology’). We compared the app scores with the doctor’s final diagnosis. We also studied the impact of things such as photo angle, lighting, type of smartphone and the person who took the photo. We found that over 16% of worrisome skin areas could not be captured by the app under ideal conditions. If participants were asked to take the photo themselves, this increased to over 70%. The app correctly identified skin cancers in 83% of cases but gave false alarms in 23%. The in-app teledermatology review reduced the number of false alarms, but this increased the number of missed skin cancers. Finally, we found important differences between different smartphones. Our findings highlight the importance of trialling apps like this with real patients in real-life setting before they are fully introduced to the public.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Kips J, Papeleu J, Shen A, et al. Artificial intelligence-based smartphone application for skin cancer detection: a prospective diagnostic accuracy study. Br J Dermatol. 2026. PMID: 41701029. doi:10.1093/bjd/ljag057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。